Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empasiprubart versus IVIg in adults with CIDP
NL-OMON60373Phase 3Recruiting
- Sponsor
- argenx
- Start
- Apr 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of empasiprubart in chronic inflammatory demyelinating polyneuropathy (CIDP) (2 arms), sponsored by argenx. Primary endpoint: Decrease of at least 1 point in adjusted INCAT score. Started Apr 2026; status: recruiting.
02
Drugs
empasiprubart
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on NL-OMON60373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60373.